Vacancy for Pharma and Science candidates in QA, Oral Solid Dosage, Liquid Dosage at Ajanta Pharma
2 August 2026

Vacancy for Pharma and Science candidates in QA, Oral Solid Dosage, Liquid Dosage at Ajanta Pharma

B.Pharm / M.Pharm. Exposure to equipment such as FBD, FBP, RMG, Coating, Compression, Capsule, Blister, etc. Manage day-to-day breakdown maintenance and ensure timely resolution with minimal downtime.
1 August 2026
Research Fellowships for Pharma and Science candidates at National Chemical Laboratory
Ph.D./MD/MS/MDS or equivalent degree or having 3years of research, teaching and design and development experience after MVSc/M.Pharm/ME/M.Tech with at least one research paper in Science Citation Indexed journal.
1 August 2026
Recruitment for Chemistry, Biochemistry, Biotechnology candidates at SJRI

The St. John's Research Institute (SJRI) is a part of the St John's National Academy of Health Sciences, which is run by the CBCI Society for Medical Education. From its inception, St. John's has set before it an ideal of excellence in academic courses as well as service to society as a result of which it has truly become holistic both in its outlook and in its approach to the problems of community health.

1 August 2026
APOTEX looking for Executive, Lead Executive
Experience in handling Change Controls related to Master Production, Packaging, and Validation documentation through QMS TrackWise.
1 August 2026
Sanofi looking for Medical Writer
Bachelors or Masters degree in Life Sciences, Pharmacy, Biotechnology, Medicine, or related healthcare discipline.
1 August 2026
FDA Flags Viatris' TOBI Podhaler Promotional Video for Misleading Usage Claims

The U.S. Food and Drug Administration (FDA) has issued an Untitled Letter to Viatris Specialty LLC, stating that a direct-to-consumer (DTC) promotional video for TOBI® PODHALER® (tobramycin inhalation powder) contains false or misleading claims regarding the product's use. According to the FDA, the promotional material misbrands the drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

1 August 2026
Sun Pharma Reports 10% Revenue Growth in Q1 FY27, India Business and Innovative Medicines Lead Performance

Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company, has announced a strong start to FY2026-27, reporting double-digit revenue growth in the first quarter ended June 30, 2026. Robust performance in the domestic formulations business and continued momentum in its innovative medicines portfolio helped the company deliver higher sales and profitability despite softer demand in the U.S. generics market.

1 August 2026
AbbVie Posts Strong Q2 2026 Results as Skyrizi and Rinvoq Drive Double-Digit Revenue Growth
AbbVie has reported strong financial results for the second quarter of 2026, driven by continued robust demand for its blockbuster immunology medicines Skyrizi and Rinvoq. The company's performance exceeded Wall Street expectations, demonstrating that its strategy to offset declining Humira sales continues to deliver positive results.
1 August 2026
Sun Pharma receives approval to manufacture and market semaglutide in Brazill

Sun Pharma announced that it has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once-weekly dosing.